Date stringdate 2012-01-01 00:00:00 2023-12-31 00:00:00 | Stock_symbol stringlengths 1 5 | Article_title stringlengths 1 255 | Article stringlengths 1 342k |
|---|---|---|---|
2023-05-18 00:00:00+00:00 | ABBV | Which Pharmaceuticals Stock Is A Better Pick: Johnson & Johnson Or Eliquis' Maker? | We believe Bristol Myers Squibb stock (NYSE: BMY) is a better pick than its industry peer, Johnson & Johnson (NYSE: JNJ). J&J trades at a higher valuation of 4.4x trailing revenues, compared to 3.1x for BMS, and this valuation gap will likely narrow over the coming years in favor of BMS, in our view. While BMS has see... |
2023-05-18 00:00:00+00:00 | ABBV | EXPLAINER-The latest on tax credit rules in Biden's climate and drugs bill | By Jarrett Renshaw and Philip Blenkinsop
May 18 (Reuters) - U.S. President Joe Biden's Inflation Reduction Act (IRA), cheered by some Democrats and the White House as a milestone in the fight against climate change, has also rankled foreign allies and global companies with its economic protectionism and prompted a new ... |
2023-05-17 00:00:00+00:00 | ABBV | Guru Fundamental Report for ABBV | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... |
2023-05-16 00:00:00+00:00 | ABBV | Notable Tuesday Option Activity: PENN, ABBV, KEYS | Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in PENN Entertainment Inc (Symbol: PENN), where a total volume of 11,973 contracts has been traded thus far today, a contract volume which is representative of approximately 1.2 million underlying shares (... |
2023-05-16 00:00:00+00:00 | ABBV | AstraZeneca to leave leading U.S. drug lobby group | By Maggie Fick
LONDON, May 16 (Reuters) - AstraZeneca AZN.L has decided to leave the main U.S. drug lobby group, the Pharmaceutical Research and Manufacturers of America (PhRMA), and pursue other ways of engaging in advocacy at the state and federal level, the company said.
AstraZeneca decided not to continue its membe... |
2023-05-16 00:00:00+00:00 | ABBV | AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It | AbbVie (ABBV) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.
Shares of this drugmaker have returned -9.1% over the past month versus the Zacks S&P 500 composite's +0.1% chan... |
2023-05-15 00:00:00+00:00 | ABBV | Guru Fundamental Report for ABBV | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... |
2023-05-15 00:00:00+00:00 | ABBV | Allergan Aesthetics Says FDA Approves SKINVIVE By JUVEDERM | (RTTNews) - Allergan Aesthetics, an AbbVie company (ABBV), announced Monday the U.S. FDA approval of SKINVIVE by JUVEDERM to improve skin smoothness of the cheeks in adults over the age of 21.
SKINVIVE by JUVEDERM is the first and only hyaluronic acid (HA) intradermal microdroplet injection for skin smoothness availabl... |
2023-05-15 00:00:00+00:00 | ABBV | IXJ, MRK, ABBV, PFE: ETF Outflow Alert | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Global Healthcare ETF (Symbol: IXJ) where we have detected an approximate $154.8 million dollar outflow -- that's a 3.6% decrease week over week (from 50,450,000 to 48,650,000). Amon... |
2023-05-12 00:00:00+00:00 | ABBV | See Which Of The Latest 13F Filers Holds AbbVie | At Holdings Channel, we have reviewed the latest batch of the 46 most recent 13F filings for the 03/31/2023 reporting period, and noticed that AbbVie Inc (Symbol: ABBV) was held by 22 of these funds. When hedge fund managers appear to be thinking alike, we find it is a good idea to take a closer look.
Before we proceed... |
2023-05-12 00:00:00+00:00 | ABBV | Guru Fundamental Report for ABBV | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... |
2023-05-11 00:00:00+00:00 | ABBV | Is WisdomTree U.S. High Dividend ETF (DHS) a Strong ETF Right Now? | The WisdomTree U.S. High Dividend ETF (DHS) made its debut on 06/16/2006, and is a smart beta exchange traded fund that provides broad exposure to the Style Box - Large Cap Value category of the market.
What Are Smart Beta ETFs?
The ETF industry has traditionally been dominated by products based on market capitalizatio... |
2023-05-11 00:00:00+00:00 | ABBV | Should You Invest in the Vanguard Health Care ETF (VHT)? | The Vanguard Health Care ETF (VHT) was launched on 01/26/2004, and is a passively managed exchange traded fund designed to offer broad exposure to the Healthcare - Broad segment of the equity market.
Retail and institutional investors increasingly turn to passively managed ETFs because they offer low costs, transparenc... |
2023-05-10 00:00:00+00:00 | ABBV | Unusual Put Option Trade in Abbvie (ABBV) Worth $4,742.50K | On May 10, 2023 at 15:19:36 ET an unusually large $4,742.50K block of Put contracts in Abbvie (ABBV) was bought, with a strike price of $160.00 / share, expiring in 9 day(s) (on May 19, 2023). Fintel tracks all large options trades, and the premium spent on this trade was 3.53 sigmas above the mean, placing it in the 1... |
2023-05-10 00:00:00+00:00 | ABBV | Guru Fundamental Report for ABBV | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... |
2023-05-10 00:00:00+00:00 | ABBV | Should WisdomTree U.S. High Dividend ETF (DHS) Be on Your Investing Radar? | Designed to provide broad exposure to the Large Cap Value segment of the US equity market, the WisdomTree U.S. High Dividend ETF (DHS) is a passively managed exchange traded fund launched on 06/16/2006.
The fund is sponsored by Wisdomtree. It has amassed assets over $1.26 billion, making it one of the average sized ETF... |
2023-05-10 00:00:00+00:00 | ABBV | Should You Buy Merck Stock At $120? | Merck stock (NYSE: MRK) is up 5% in a month, faring slightly better than the broader markets, with the S&P500 up 1%. Although the company posted upbeat Q1 results late last month, we believe MRK stock is fully valued. Merck’s revenues were down 9% to $14.5 billion in Q1’23, compared to our forecast of $13.9 billion. Th... |
2023-05-09 00:00:00+00:00 | ABBV | Why Viking Therapeutics Stock Wobbled Today | What happened
Shares of clinical-stage biotech Viking Therapeutics (NASDAQ: VKTX) fell by as much as 4.8% on exceptionally low volume during the first hour of trading Tuesday morning. Since this mid-single-digit dip, the biotech's shares have battled back over the course of today's trading session.
As of 2:33 p.m. ET T... |
2023-05-09 00:00:00+00:00 | ABBV | Noteworthy Tuesday Option Activity: HOLX, ABBV, JNJ | Among the underlying components of the S&P 500 index, we saw noteworthy options trading volume today in Hologic Inc (Symbol: HOLX), where a total of 7,207 contracts have traded so far, representing approximately 720,700 underlying shares. That amounts to about 54.7% of HOLX's average daily trading volume over the past ... |
2023-05-09 00:00:00+00:00 | ABBV | AbbVie Says Health Canada Approves RINVOQ To Treat Adults With Active Nr-axSpA | (RTTNews) - AbbVie (ABBV) announced Tuesday that Health Canada has approved RINVOQ (upadacitinib, 15 mg), the first oral, once-daily selective and reversible JAK inhibitor for the treatment of adults with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation who have had an ina... |
2023-05-08 00:00:00+00:00 | ABBV | 7 Dividend Stocks That Will Pay You Through Any Market Turmoil | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
While there’s nothing quite as exciting as betting everything on a hot growth enterprise, prudent investors may want to consider the best dividend stocks for market crash. In late April, CNBC reported that investors face the threat of persistently higher in... |
2023-05-08 00:00:00+00:00 | ABBV | Guru Fundamental Report for ABBV | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... |
2023-05-06 00:00:00+00:00 | ABBV | 1 Relatively Safe Dividend Growth Stock to Buy Hand Over Fist Right Now | If you can buy high-quality dividend stocks when other investors sour on them, you can plant the seeds for robust returns in the future. And that's exactly why it might be worth buying shares of AbbVie (NYSE: ABBV) like it's about to go out of style.
Despite its fully expected, yet ultimately abysmal, first-quarter ear... |
2023-05-06 00:00:00+00:00 | ABBV | Looking for Steady, Passive Income? Buy AbbVie Stock | Dividend growth investing revolves around selecting only the most reliable businesses for your portfolio. This can be measured by consecutive years of dividend growth.
With 51 consecutive years of dividend growth to its credit (including time spent as part of Abbott Laboratories), AbbVie (NYSE: ABBV) certainly has such... |
2023-05-06 00:00:00+00:00 | ABBV | 3 Great Income Stocks That Retirees Should Love | Most Americans don't have to wait until they're retired to know that Social Security benefits won't be enough to maintain their current lifestyle. If they pay any attention to retirement planning advice, they know they will need other sources of income as well. Investing in dividend stocks is one great way to generate ... |
2023-05-05 00:00:00+00:00 | ABBV | XLV: 5 Reasons to Put This Healthcare ETF on Your Radar | The Healthcare Select Sector SPDR ETF (NYSEARCA:XLV) has had a relatively quiet 2023 thus far. XLV has a loss of about 1.1% year-to-date, but it looks like an attractive investment vehicle in the current environment -- here are five reasons why.
1. Healthcare is Defensive
Between soaring inflation, rising interest ra... |
2023-05-05 00:00:00+00:00 | ABBV | VYM, JPM, CVX, ABBV: ETF Inflow Alert | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Vanguard High Dividend Yield ETF (Symbol: VYM) where we have detected an approximate $233.6 million dollar inflow -- that's a 0.5% increase week over week in outstanding units (from 463,654,... |
2023-05-04 00:00:00+00:00 | ABBV | 7 Stock Upgrades and Downgrades Alerts You Cannot Ignore | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Analyst stock upgrades and downgrades create powerful headlines that will move the underlying shares. Investors should take advantage of the price swings analysts create, especially when they make the wrong calls.
Stock price changes are noisy. Investors ma... |
2023-05-04 00:00:00+00:00 | ABBV | 7 Dividend-Paying Large-Cap Stocks to Buy in May | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Large-cap stocks are those that have a market capitalization above $10 billion and are synonymously known as big cap stocks. A company’s market capitalization is calculated by multiplying the share price by the number of shares outstanding. By that metric, ... |
2023-05-04 00:00:00+00:00 | ABBV | June 23rd Options Now Available For AbbVie (ABBV) | Investors in AbbVie Inc (Symbol: ABBV) saw new options begin trading today, for the June 23rd expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABBV options chain for the new June 23rd contracts and identified one put and one call contract of particular interest.
The put contract a... |
2023-05-03 00:00:00+00:00 | ABBV | 2 Things About AbbVie That Investors Are Ignoring | Investors were ready for declines in AbbVie's (NYSE: ABBV) blockbuster immunology drug Humira. The product now is facing competition in the U.S. So, seeing a 26% drop in Humira's U.S. first-quarter sales wasn't a surprise. And AbbVie has been grooming its newer immunology drugs -- Rinvoq and Skyrizi -- to eventually co... |
2023-05-03 00:00:00+00:00 | ABBV | Guru Fundamental Report for ABBV | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... |
2023-05-02 00:00:00+00:00 | ABBV | Vertex Pharmaceuticals Just Lost a Potential Rival. Is the Stock a Buy? | Vertex Pharmaceuticals (NASDAQ: VRTX) is the global leader in cystic fibrosis (CF) treatment. The company is known for its combination therapies targeting a defective protein that causes the disease's devastating symptoms.
But one possible threat to market share waited in the wings. AbbVie (NYSE: ABBV) had shepherded i... |
2023-05-02 00:00:00+00:00 | ABBV | AmerisourceBergen raises profit forecast on demand for pricier specialty drugs | May 2 (Reuters) - AmerisourceBergen Corp ABC.N on Tuesday raised full-year profit forecast and beat estimates for the second quarter, as the drug distributor benefited from demand for costly specialty therapies.
The Pennsylvania-based company has been looking to diversify its specialty services business, through which ... |
2023-05-02 00:00:00+00:00 | ABBV | Vertex Pharmaceuticals Stock Is an Even Better Buy Now Thanks to AbbVie | While the overall market plummeted last year, shares of Vertex Pharmaceuticals (NASDAQ: VRTX) skyrocketed 31%. So far in 2023, the stock is up nearly 20%.
I've shouted from the rooftop for a long time that Vertex is one of the best biotech stocks around. And I'm more convinced of that than ever after a key development ... |
2023-05-02 00:00:00+00:00 | ABBV | High-Yield Pfizer Falls Off The COVID Cliff, And Survives | Pfizer (NYSE: PFE) was expected to post a significant decline in revenue and earnings because of the slowing COVID business, and it did. However, the takeaway from the report is that business is better than expected, the company is growing at the core level, and the pipeline of new products is robust. That’s important ... |
2023-05-02 00:00:00+00:00 | ABBV | Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know | AbbVie (ABBV) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.
Shares of this drugmaker have returned -4.2% over the past month versus the Zacks S&P 500 composite's +1.5% chan... |
2023-05-01 00:00:00+00:00 | ABBV | Unusual Put Option Trade in Abbvie (ABBV) Worth $1,585.00K | On May 1, 2023 at 11:32:44 ET an unusually large $1,585.00K block of Put contracts in Abbvie (ABBV) was sold, with a strike price of $150.00 / share, expiring in 627 day(s) (on January 17, 2025). Fintel tracks all large options trades, and the premium spent on this trade was 5.38 sigmas above the mean, placing it in th... |
2023-05-01 00:00:00+00:00 | ABBV | Notable Monday Option Activity: ABBV, ORCL, MTCH | Among the underlying components of the S&P 500 index, we saw noteworthy options trading volume today in AbbVie Inc (Symbol: ABBV), where a total of 27,571 contracts have traded so far, representing approximately 2.8 million underlying shares. That amounts to about 52.6% of ABBV's average daily trading volume over the p... |
2023-05-01 00:00:00+00:00 | ABBV | Where Will AbbVie Be in 5 Years? | On paper, drugmaker AbbVie (NYSE: ABBV) isn't having the best year. The company recently lost patent exclusivity in the U.S for its biggest cash cow, immunology medicine Humira. This product has been the key asset for AbbVie over the 10 years since it split from Abbott Laboratories, so this is a big deal.
But even if A... |
2023-05-01 00:00:00+00:00 | ABBV | Guru Fundamental Report for ABBV | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... |
2023-05-01 00:00:00+00:00 | ABBV | AbbVie Stock Plunged: Should You Buy the Dip? | AbbVie (NYSE: ABBV) spent 11 weeks building solid momentum. Its stock climbed more than 14% during the period. But it took only one day to wipe out most of the gain.
The drugmaker's shares plunged last Thursday after AbbVie announced its first-quarter results. Although the pharma stock rebounded slightly on Friday, it'... |
2023-04-30 00:00:00+00:00 | ABBV | AbbVie's Blockbuster Is Falling Fast. Time to Sell? | Last week wasn't a great one for a lot of pharmaceutical stock investors. Shares of AbbVie (NYSE: ABBV) dropped by about 8% on Thursday, April 27. The market was responding to an earnings report that was the company's first since its lead product, Humira, lost patent-protected exclusivity in the U.S. market.
Humira los... |
2023-04-29 00:00:00+00:00 | ABBV | 3 Unstoppable Stocks to Buy Right Now | The laws of physics apply in some ways to investing. For example, some stocks have inertia -- they just can't break out of their rut. Others, though, either have momentum or the likelihood of gaining it in the future. Those are the kinds of stocks that are hard to keep down.
Three Motley Fool contributors have thoughts... |
2023-04-28 00:00:00+00:00 | ABBV | AbbVie (ABBV) Q1 2023 Earnings Call Transcript | Image source: The Motley Fool.
AbbVie (NYSE: ABBV)
Q1 2023 Earnings Call
Apr 27, 2023, 9:00 a.m. ET
Contents:
Prepared Remarks
Questions and Answers
Call Participants
Prepared Remarks:
Operator
Good morning, and thank you for standing by. Welcome to the AbbVie first quarter 2023earnings conference call All participant... |
2023-04-28 00:00:00+00:00 | ABBV | Wells Fargo Maintains Abbvie (ABBV) Overweight Recommendation | Fintel reports that on April 28, 2023, Wells Fargo maintained coverage of Abbvie (NYSE:ABBV) with a Overweight recommendation.
Analyst Price Forecast Suggests 13.11% Upside
As of April 24, 2023, the average one-year price target for Abbvie is 168.39. The forecasts range from a low of 136.35 to a high of $210.00. The av... |
2023-04-28 00:00:00+00:00 | ABBV | Morgan Stanley Maintains Abbvie (ABBV) Overweight Recommendation | Fintel reports that on April 28, 2023, Morgan Stanley maintained coverage of Abbvie (NYSE:ABBV) with a Overweight recommendation.
Analyst Price Forecast Suggests 13.11% Upside
As of April 24, 2023, the average one-year price target for Abbvie is 168.39. The forecasts range from a low of 136.35 to a high of $210.00. The... |
2023-04-28 00:00:00+00:00 | ABBV | Guru Fundamental Report for ABBV | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... |
2023-04-28 00:00:00+00:00 | ABBV | Guggenheim Maintains Abbvie (ABBV) Buy Recommendation | Fintel reports that on April 28, 2023, Guggenheim maintained coverage of Abbvie (NYSE:ABBV) with a Buy recommendation.
Analyst Price Forecast Suggests 13.11% Upside
As of April 24, 2023, the average one-year price target for Abbvie is 168.39. The forecasts range from a low of 136.35 to a high of $210.00. The average pr... |
2023-04-28 00:00:00+00:00 | ABBV | 5 Dividend Aristocrats Where Analysts See Capital Gains | To become a "Dividend Aristocrat," a dividend paying company must accomplish an incredible feat: consistently increase shareholder dividends every year for at least 20 consecutive years. Companies with this kind of track record tend to attract a lot of investor attention — and furthermore, "tracking" funds that follow ... |
2023-04-28 00:00:00+00:00 | ABBV | How AI Is Revolutionizing Tech, and Why You Should Invest in These Leading Companies | Artificial intelligence (AI) permeated industries for years, but the release of ChatGPT thrust it into the limelight. It's the talk of the investment community and around the water coolers across the country. But what exactly is it?
AI extends far beyond "intelligent" (and sometimes sinister) robots in the movies or Ch... |
2023-04-27 00:00:00+00:00 | ABBV | US STOCKS-Wall St rallies as earnings season boost offsets economy worries | By Sinéad Carew, Sruthi Shankar and Ankika Biswas
April 27 (Reuters) - The tech-heavy Nasdaq led a Wall Street rally on Thursday as a strong quarterly report from Facebook parent Meta Platforms Inc overshadowed concerns over slowing U.S. economic growth.
Shares in Meta META.Osoared to touch the highest in more than a y... |
2023-04-27 00:00:00+00:00 | ABBV | Drugmakers scout for deals, ramp up research spending | By Manas Mishra and Patrick Wingrove
April 27 (Reuters) - Drugmakers including Merck & Co MRK.N, AstraZeneca Plc AZN.L and AbbVie Inc ABBV.N said on Thursday they are open to acquisitions and reported a ramp up in research and development spending as the industry's larger players look for new sources of future revenue.... |
2023-04-27 00:00:00+00:00 | ABBV | AbbVie (ABBV) Shares Cross 4% Yield Mark | Looking at the universe of stocks we cover at Dividend Channel, in trading on Thursday, shares of AbbVie Inc (Symbol: ABBV) were yielding above the 4% mark based on its quarterly dividend (annualized to $5.92), with the stock changing hands as low as $147.16 on the day. Dividends are particularly important for investor... |
2023-04-27 00:00:00+00:00 | ABBV | US STOCKS-Wall St rallies as Meta earnings offset economy worries | For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window.
Lower inventories restrains Q1 US economic growth
Meta up, touts AI might as digital ads boost outlook
Eli Lilly up on annual profit forecast raise
Amazon.com soars, earnings due after market close
Indexes up: Do... |
2023-04-27 00:00:00+00:00 | ABBV | Why AbbVie Stock Is Crashing Today | What happened
Shares of the pharmaceutical giant AbbVie (NYSE: ABBV) fell by as much as 9% in early morning trading Thursday. The drugmaker's shares have recovered since hitting this intra-day low, but they were still down by a hefty 7.8% as of 1:14 p.m. ET Thursday afternoon.
What sparked this sell-off? Ahead of the o... |
2023-04-27 00:00:00+00:00 | ABBV | AbbVie (ABBV) Q1 Earnings Beat, Skyrizi Sales Underperform | AbbVie Inc. ABBV reported adjusted earnings of $2.46 per share for the first quarter of 2023, beating the Zacks Consensus Estimate and our estimate, which stood at $2.44 and $2.40, respectively. The reported earnings also exceeded the guidance of $2.31-$2.41. Earnings declined 22.2% year over year.
ABBV’s revenues of $... |
2023-04-27 00:00:00+00:00 | ABBV | ABBV Makes Notable Cross Below Critical Moving Average | In trading on Thursday, shares of AbbVie Inc (Symbol: ABBV) crossed below their 200 day moving average of $150.76, changing hands as low as $147.51 per share. AbbVie Inc shares are currently trading off about 8.6% on the day. The chart below shows the one year performance of ABBV shares, versus its 200 day moving avera... |
2023-04-27 00:00:00+00:00 | ABBV | AbbVie misses sales estimates for some drugs, shares tumble | Adds details on drug sales, shares
April 27 (Reuters) - AbbVie Inc ABBV.N on Thursday missed quarterly revenue estimates for some of its major drugs, overshadowing an increased annual profit forecast and driving shares down 5% in premarket trade.
The company recorded $3.54 billion in sales of its blockbuster drug Humir... |
2023-04-27 00:00:00+00:00 | ABBV | S&P 500 Movers: ALGN, META | In early trading on Thursday, shares of Meta Platforms topped the list of the day's best performing components of the S&P 500 index, trading up 14.7%. Year to date, Meta Platforms registers a 99.6% gain.
And the worst performing S&P 500 component thus far on the day is Align Technology, trading down 11.1%. Align Techno... |
2023-04-27 00:00:00+00:00 | ABBV | Drugmakers post healthy results as growth drivers shine | April 27 (Reuters) - Drugmakers including Merck & Co MRK.N, Eli Lilly LLY.N and AstraZeneca Plc AZN.L reported strong first-quarter earnings and several raised their expectations for 2023, as post-pandemic demand for cancer and other treatments jumped.
The earnings on Thursday shine a spotlight on the pharmaceuticals s... |
2023-04-27 00:00:00+00:00 | ABBV | Health Care Sector Update for 04/27/2023: ABBV, MRK, AZN, XLV, IBB | Health care stocks were narrowly mixed pre-bell Thursday. The Health Care Select Sector SPDR Fund (XLV) was 0.2% higher and the iShares Biotechnology ETF (IBB) was marginally lower.
AbbVie (ABBV) was declining by more than 3% after it reported Q1 adjusted earnings of $2.46 per diluted share, compared with $3.16 a year ... |
2023-04-27 00:00:00+00:00 | ABBV | AbbVie (ABBV) Q1 Earnings and Revenues Top Estimates | AbbVie (ABBV) came out with quarterly earnings of $2.46 per share, beating the Zacks Consensus Estimate of $2.44 per share. This compares to earnings of $3.16 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 0.82%. A quarter ago, it was e... |
2023-04-27 00:00:00+00:00 | ABBV | 1 Dividend Stock to Buy Hand Over Fist in May and 1 to Avoid | Some dividend stocks will pay a tidy and ever-increasing sum into your account for years. Others will run out of steam and slash your quarterly paycheck. Ideally, you'd buy shares of the first kind and avoid the second kind. So here's one example of each.
Image source: Getty Images.
1. AbbVie
AbbVie (NYSE: ABBV) is a m... |
2023-04-27 00:00:00+00:00 | ABBV | AbbVie Q1 Profit Drops, Inline With Estimates | (RTTNews) - AbbVie (ABBV) reported earnings for first quarter that decreased from last year in line with the Street estimates.
The company's earnings totaled $239 million, or $0.13 per share. This compares with $4.49 billion, or $2.51 per share, in last year's first quarter.
Excluding items, AbbVie reported adjusted ea... |
2023-04-27 00:00:00+00:00 | ABBV | AbbVie raises annual profit forecast as Humira demand holds steady | Adds missing words in headline
April 27 (Reuters) - AbbVie Inc ABBV.N on Thursday raised its 2023 profit forecast on a less-than-feared hit to U.S. sales of arthritis drug Humira from rival biosimilar drugs.
The company now expects 2023 adjusted earnings to be between $10.72 and $11.12 per share, from between $10.62 an... |
2023-04-27 00:00:00+00:00 | ABBV | SPYG, CVX, MRK, ABBV: ETF Inflow Alert | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR Portfolio S&P 500 Growth ETF (Symbol: SPYG) where we have detected an approximate $199.9 million dollar inflow -- that's a 1.3% increase week over week in outstanding units (from 288,80... |
2023-04-26 00:00:00+00:00 | ABBV | Drug/Biotech Stocks' Q1 Earnings Due Apr 27: LLY, ABBV & More | The first-quarter 2023 reporting cycle of the Medical sector is about to pick up pace this week. The sector mainly comprises pharma/biotech and medical device companies.
The earnings season for the Medical sector kicked off last week when bellwether Johnson & Johnson reported better-than-expected first-quarter results.... |
2023-04-26 00:00:00+00:00 | ABBV | Guru Fundamental Report for ABBV | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... |
2023-04-26 00:00:00+00:00 | ABBV | Earnings Beat In The Cards For Merck Stock? | Merck (NYSE: MRK) will report its Q1 2023 results on Thursday, April 27. We expect MRK stock to trade higher, with its revenue and earnings expected to be above the street estimates. Although the company should benefit from continued market share gains for Keytruda and Gardasil, among other products, forex headwinds an... |
2023-04-25 00:00:00+00:00 | ABBV | This Supercharged Dividend King Stock Might Soon Run Out of Steam | AbbVie (NYSE: ABBV) has been a top growth and passive-income machine for investors since splitting off from parent company Abbott Laboratories (NYSE: ABT) in 2013. Speaking to this point, the drugmaker has grown its annual revenue by a healthy 215% and its dividend payout by 270% since becoming an independent entity.
A... |
2023-04-25 00:00:00+00:00 | ABBV | Health Care Sector Update for 04/25/2023: ENTA, ABBV, TCON, IMAB, BIIB, ABUS | Health care stocks were lower late Tuesday afternoon, with the NYSE Health Care Index falling 0.7% and the Health Care Select Sector SPDR Fund (XLV) down 1.1%.
The iShares Biotechnology ETF (IBB) was decreasing 1.9%.
In company news, Enanta Pharmaceuticals (ENTA) said it sold its 54.5% of future royalty payments from A... |
2023-04-25 00:00:00+00:00 | ABBV | Is Global X SuperDividend U.S. ETF (DIV) a Strong ETF Right Now? | Launched on 03/11/2013, the Global X SuperDividend U.S. ETF (DIV) is a smart beta exchange traded fund offering broad exposure to the Style Box - All Cap Value category of the market.
What Are Smart Beta ETFs?
For a long time now, the ETF industry has been flooded with products based on market capitalization weighted i... |
2023-04-25 00:00:00+00:00 | ABBV | Should SPDR Portfolio S&P 500 High Dividend ETF (SPYD) Be on Your Investing Radar? | Looking for broad exposure to the Large Cap Value segment of the US equity market? You should consider the SPDR Portfolio S&P 500 High Dividend ETF (SPYD), a passively managed exchange traded fund launched on 10/21/2015.
The fund is sponsored by State Street Global Advisors. It has amassed assets over $6.77 billion, ma... |
2023-04-24 00:00:00+00:00 | ABBV | Guru Fundamental Report for ABBV | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... |
2023-04-24 00:00:00+00:00 | ABBV | Can Amgen (AMGN) Keep the Earnings Streak Alive in Q1? | We expect Amgen AMGN to beat expectations when it reports first-quarter 2023 results on Apr 27, after market close. In the last reported quarter, the company delivered an earnings surprise of 1.24%.
This large biotech’s performance has been strong, with earnings beating estimates in all the trailing four quarters. The ... |
2023-04-24 00:00:00+00:00 | ABBV | AbbVie (ABBV) to Report Q1 Earnings: What's in the Cards? | AbbVie ABBV will report first-quarter 2023 results on Apr 27, before market open. In the last reported quarter, the company delivered an earnings surprise of 1.69%.
This large drugmaker’s performance has been impressive, with its earnings beating estimates in each of the trailing four quarters. The company has a traili... |
2023-04-23 00:00:00+00:00 | ABBV | The Best Stocks to Invest $20,000 in Right Now | If you have $20,000 to invest, you could put it all in one stock -- or you could invest across several. I favor buying a few stocks that can each offer you something different. For instance, one may pay you a top-notch dividend, another may offer you a solid track record of earnings growth, and a third might promise th... |
2023-04-22 00:00:00+00:00 | ABBV | 3 Top Dividend Kings to Buy for the Long Haul | Investing in Dividend Kings is just one part of a solid long-term strategy. The attraction is that their long history of annual dividend increases (50 consecutive years or more) reflects well on the companies' business growth and stability.
That doesn't mean that they won't see their shares jump or fall; they're not im... |
2023-04-21 00:00:00+00:00 | ABBV | Noteworthy Friday Option Activity: ABBV, PEN, DE | Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in AbbVie Inc (Symbol: ABBV), where a total of 21,236 contracts have traded so far, representing approximately 2.1 million underlying shares. That amounts to about 50.2% of ABBV's average daily trading volume over ... |
2023-04-21 00:00:00+00:00 | ABBV | Pharma Stock Roundup: JNJ Beats on Q1 Earnings, MRK to Buy RXDX & Other Updates | This week, J&J JNJ began the first-quarter earnings season for the drug and biotech sector with strong results. Merck MRK offered to buy Prometheus Biosciences RXDX for around $10.8 billion. The FDA approved AbbVie’s ABBV Qulipta for chronic migraine indication.
Recap of the Week’s Most Important Stories
J&J Begins Q1 ... |
2023-04-20 00:00:00+00:00 | ABBV | Abbvie Inc Shares Close in on 52-Week High - Market Mover | Abbvie Inc (ABBV) shares closed today at 1.6% below its 52 week high of $165.01, giving the company a market cap of $285B. The stock is currently up 2.0% year-to-date, up 7.2% over the past 12 months, and up 120.6% over the past five years. This week, the Dow Jones Industrial Average fell 0.7%, and the S&P 500 fell 0.4... |
2023-04-20 00:00:00+00:00 | ABBV | Earnings Preview: AbbVie (ABBV) Q1 Earnings Expected to Decline | Wall Street expects a year-over-year decline in earnings on lower revenues when AbbVie (ABBV) reports results for the quarter ended March 2023. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actua... |
2023-04-19 00:00:00+00:00 | ABBV | Is Merck Stock a Screaming Buy After This $11 Billion Acquisition? | Earlier this week, Merck (NYSE: MRK) went shopping and purchased the precision-medicine company Prometheus Biosciences (NASDAQ: RXDX) for $200 a share, for a total value of $10.8 billion. The transaction is expected to close in the third quarter of 2023.
The deal centers around PRA023, the late-stage autoimmune disorde... |
2023-04-19 00:00:00+00:00 | ABBV | Guru Fundamental Report for ABBV | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... |
2023-04-19 00:00:00+00:00 | ABBV | Noteworthy ETF Inflows: IWB, JPM, CVX, ABBV | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Russell 1000 ETF (Symbol: IWB) where we have detected an approximate $216.1 million dollar inflow -- that's a 0.8% increase week over week in outstanding units (from 126,100,000 to 1... |
2023-04-18 00:00:00+00:00 | ABBV | COWZ ETF: A Cash Cow for Your Portfolio | The market is flooded with plenty of growth ETFs, dividend ETFs, and sector-specific ETFs. How about an ETF that takes an entirely different approach? That’s exactly what the Pacer Cash Cows ETF (BATS:COWZ) does, and it has produced phenomenal annualized total returns of ~31% over the past three years (as of the end of... |
2023-04-18 00:00:00+00:00 | ABBV | AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know | AbbVie (ABBV) closed at $159.59 in the latest trading session, marking a -0.99% move from the prior day. This move lagged the S&P 500's daily gain of 0.09%. Elsewhere, the Dow lost 0.03%, while the tech-heavy Nasdaq lost 2.51%.
Coming into today, shares of the drugmaker had gained 3.24% in the past month. In that same ... |
2023-04-17 00:00:00+00:00 | ABBV | FDA Approves AbbVie's Qulipta For Preventive Treatment Of Migraine In Adults | (RTTNews) - AbbVie (ABBV) said that the U.S. Food and Drug Administration approved expanding the indication of Qulipta (atogepant) for the preventive treatment of migraine in adults.
The company noted that the approval makes Qulipta the first and only oral calcitonin gene-related peptide (CGRP) receptor antagonist appr... |
2023-04-17 00:00:00+00:00 | ABBV | Guru Fundamental Report for ABBV | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... |
2023-04-17 00:00:00+00:00 | ABBV | European Commission Approves AbbVie's Rinvoq To Treat Severely Active Crohn's Disease | (RTTNews) - The European Commission approved Rinvoq (upadacitinib, 45 mg [induction dose] and 15 mg and 30 mg [maintenance doses]) as the first oral Janus Kinase (JAK) inhibitor for the treatment of adult patients with moderately to severely active Crohn's disease who have had an inadequate response, lost response or w... |
2023-04-16 00:00:00+00:00 | ABBV | 3 Stocks You Can Keep Forever | As most investors well know, there is no sure thing in the markets. But promising investments still abound. Three to consider now are AbbVie (NYSE: ABBV), Parker-Hannifin (NYSE: PH), and Carlisle Companies (NYSE: CSL). All three stocks have outpaced the S&P 500 in terms of total return over the past five years and each... |
2023-04-16 00:00:00+00:00 | ABBV | 3 Reasons Why I Regret Selling AbbVie | At the end of 2021, I unceremoniously dumped my shares of AbbVie (NYSE: ABBV) stock, which were worth a grand total of around $2,095, marking a total return of 40% on top of what I had initially invested 13 months prior.
While I'm certainly quite glad that I picked up a decent return in a very short period, I admit tod... |
2023-04-15 00:00:00+00:00 | ABBV | Guru Fundamental Report for ABBV | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... |
2023-04-15 00:00:00+00:00 | ABBV | 3 Dividend Stocks to Buy and Hold for the Next Decade | Some stocks are keepers. The best ones even pay you to hold them for years via generous dividends. Three Motley Fool contributors identified their picks for dividend stocks to buy and hold for the next decade. Here's why they chose AbbVie (NYSE: ABBV), Gilead Sciences (NASDAQ: GILD), and Johnson & Johnson (NYSE: JNJ).
... |
2023-04-14 00:00:00+00:00 | ABBV | J&J (JNJ) to Initiate Q1 Earnings Season for Pharma Sector | Johnson & Johnson JNJ will report first-quarter 2023 results on Apr 18, before market open. In the last reported quarter, the company delivered an earnings surprise of 5.86%.
The healthcare bellwether’s performance has been pretty impressive, with the company exceeding earnings expectations in each of the trailing four... |
2023-04-14 00:00:00+00:00 | ABBV | Pharma Stock Roundup: FDA Rejects LLY's Mirikizumab, NVO Ups 2023 Sales & Profit View | This week, Novo Nordisk NVO raised its previously issued sales and operating profit growth guidance for 2023 due to better-than-expected sales performance of its drugs, Wegovy and Ozempic. Eli Lilly LLY and Merck MRK announced pipeline setbacks. AbbVie ABBV voluntarily withdrew accelerated approvals granted for two blo... |
2023-04-14 00:00:00+00:00 | ABBV | Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock | AbbVie (ABBV) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.
Shares of this drugmaker have returned +4.8% over the past month versus the Zacks S&P 500 composite's +7.7% chan... |
2023-04-14 00:00:00+00:00 | ABBV | UnitedHealth ups profit view as lower medical costs drive quarterly beat | adds details on forecast
April 14 (Reuters) - UnitedHealth Group Inc UNH.Nbeat Wall Street estimates for quarterly profit on Friday and raised its annual forecast, after a slow recovery in non-urgent procedures helped lower medical costs at its insurance unit.
The industry bellwether expects costs from medical claims t... |
2023-04-14 00:00:00+00:00 | ABBV | UnitedHealth Group beats quarterly profit estimates on lower medical costs | April 14 (Reuters) - UnitedHealth Group Inc's UNH.N quarterly profit beat Wall Street estimates on Friday, as a slow recovery in non-urgent procedures helped lower medical costs at its insurance unit.
Excluding items, the company reported a profit of $6.26 per share for the first quarter, beating analysts' average esti... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.